Syon Capital LLC Acquires Shares of 7,306 Revolution Medicines, Inc. (NASDAQ:RVMD)

Syon Capital LLC purchased a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 7,306 shares of the company's stock, valued at approximately $320,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. IFP Advisors Inc acquired a new position in Revolution Medicines in the fourth quarter valued at $34,000. Sterling Capital Management LLC boosted its position in shares of Revolution Medicines by 588.7% during the 4th quarter. Sterling Capital Management LLC now owns 1,956 shares of the company's stock valued at $86,000 after purchasing an additional 1,672 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in Revolution Medicines by 368.3% in the fourth quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company's stock worth $90,000 after purchasing an additional 1,613 shares in the last quarter. Daiwa Securities Group Inc. lifted its stake in Revolution Medicines by 521.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 3,787 shares of the company's stock valued at $165,000 after buying an additional 3,178 shares during the period. Finally, Avanza Fonder AB bought a new position in shares of Revolution Medicines during the 4th quarter worth approximately $173,000. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Revolution Medicines

In related news, CFO Jack Anders sold 1,864 shares of Revolution Medicines stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $72,770.56. Following the sale, the chief financial officer now directly owns 115,006 shares in the company, valued at $4,489,834.24. The trade was a 1.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Margaret A. Horn sold 3,058 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $119,384.32. Following the completion of the transaction, the chief operating officer now owns 153,533 shares of the company's stock, valued at approximately $5,993,928.32. This trade represents a 1.95 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 16,660 shares of company stock valued at $650,406. 8.00% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Stifel Nicolaus dropped their target price on shares of Revolution Medicines from $78.00 to $64.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. UBS Group raised their target price on Revolution Medicines from $65.00 to $71.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Needham & Company LLC reaffirmed a "buy" rating and set a $59.00 price target on shares of Revolution Medicines in a research note on Tuesday, April 8th. HC Wainwright boosted their price objective on Revolution Medicines from $72.00 to $73.00 and gave the company a "buy" rating in a report on Monday, March 3rd. Finally, Wedbush reaffirmed an "outperform" rating and set a $67.00 target price on shares of Revolution Medicines in a research report on Monday. Twelve investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $66.67.

Revolution Medicines Stock Up 7.0 %

Shares of Revolution Medicines stock traded up $2.70 during trading on Monday, reaching $41.47. 2,872,304 shares of the stock were exchanged, compared to its average volume of 1,437,485. Revolution Medicines, Inc. has a 1 year low of $29.17 and a 1 year high of $62.40. The firm has a market cap of $7.71 billion, a price-to-earnings ratio of -11.55 and a beta of 1.37. The stock's fifty day moving average is $37.42 and its 200 day moving average is $43.95.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($1.12) earnings per share for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.11). Equities analysts forecast that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.